{"id":544982,"date":"2025-10-09T00:00:00","date_gmt":"2025-10-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2025-biopharma-multiple-sclerosis-current-treatment-treatment-algorithms-claims-data-analysis-multiple\/"},"modified":"2026-04-30T11:10:51","modified_gmt":"2026-04-30T11:10:51","slug":"algocg0032-2025-biopharma-multiple-sclerosis-current-treatment-treatment-algorithms-claims-data-analysis-multiple","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0032-2025-biopharma-multiple-sclerosis-current-treatment-treatment-algorithms-claims-data-analysis-multiple\/","title":{"rendered":"Multiple Sclerosis &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Multiple Sclerosis (US)"},"content":{"rendered":"<p>The treatment landscape for multiple sclerosis (<abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr>) in the U.S. is rapidly evolving, with over 20 immunomodulatory disease-modifying therapies (<abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s) available and more in development. The market reflects the disease\u2019s heterogeneity, personalized treatment approaches, and the distinct clinical profiles of each <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>. As new therapies launch and generics increase competition, the space grows more crowded. Meanwhile, early use of high-efficacy drugs is replacing traditional escalation strategies. For companies entering or operating in this market, understanding where their products\u2014especially next-in-class options\u2014fit is critical. Our Treatment Algorithms study analyses national patient-level claims data to track therapy progression by line of therapy, brand-level persistence and compliance, and current <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr> positioning.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> patients?<\/li>\n<li>How have anti-CD20 monoclonal antibodies been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"4900\" title=\"multiple sclerosis\">MS<\/abbr> patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>How have the availability of generic oral <abbr data-abbreviation-entity=\"5066\" title=\"disease-modifying therapy\">DMT<\/abbr>s influenced treatment decisions and prescribing behavior?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Product d<\/strong><strong>escription<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Mylan \/ Viatris, Novartis, Sanofi, Teva, TG Therapeutics<\/p>\n<p><strong>Key drugs:<\/strong> Aubagio \/ teriflunomide, Bafiertam, Briumvi, Copaxone \/ glatiramer acetate, Gilenya \/ fingolimod, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ocrevus Zunovo, Ponvory, Tecfidera \/ dimethyl fumarate, Tysabri, Vumerity, Zeposia<\/p>\n<p><strong>Key analysis provided<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Brand \/ therapy usage across patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flow.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Dashboard featuring interactive visuals, easy navigation, and expanded analyses.<\/li>\n<\/ul>\n<ul class=\"round-bullets\">\n<\/ul>\n","protected":false},"template":"","class_list":["post-544982","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/544982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/544982\/revisions"}],"predecessor-version":[{"id":545215,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/544982\/revisions\/545215"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=544982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}